Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
NCT03960177Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2019
- Primary completion
- Dec 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glucarpidase in osteosarcoma (OS), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of subjects completing 4 planned doses of high dose methotrexate (HDMTX) at 10 weeks. Started Mar 2019; status: completed.
02
Drugs
glucarpidase
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03960177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960177.